Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial. (linkinghub.elsevier.com)

Authors: Paterson DL … Harris PNA Journal: Lancet Infectious Diseases Published: 2026-02-01 DOI: https://doi.org/10.1016/S1473-3099(25)00469-4